Incyte Corporation $INCY Stock: VIRGINIA RETIREMENT SYSTEMS ET Al Grows Position

VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in shares of Incyte Corporation (NASDAQ:INCY) by 54.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 844,389 shares of the biopharmaceutical company’s stock after purchasing an additional 299,014 shares during the period. Incyte accounts for 0.6% of VIRGINIA RETIREMENT SYSTEMS ET Al’s portfolio, making the stock its 23rd largest position. VIRGINIA RETIREMENT SYSTEMS ET Al owned about 0.42% of Incyte worth $102,467,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of Incyte in the 2nd quarter valued at $2,044,189,000. Wellington Management Group LLP increased its holdings in shares of Incyte by 9.5% during the 2nd quarter. Wellington Management Group LLP now owns 3,575,521 shares of the biopharmaceutical company’s stock worth $405,321,000 after buying an additional 309,385 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Incyte by 10.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,975,544 shares of the biopharmaceutical company’s stock worth $185,873,000 after buying an additional 187,354 shares during the last quarter. Legal & General Group Plc purchased a new position in shares of Incyte in the 2nd quarter worth $182,054,000. Finally, Pacer Advisors Inc. raised its position in shares of Incyte by 2.2% in the 1st quarter. Pacer Advisors Inc. now owns 1,741,061 shares of the biopharmaceutical company’s stock worth $163,869,000 after buying an additional 37,790 shares during the period. Institutional investors and hedge funds own 96.97% of the company’s stock.

Analyst Upgrades and Downgrades

INCY has been the subject of a number of research reports. Royal Bank Of Canada boosted their price target on Incyte from $114.00 to $117.00 and gave the company a “sector perform” rating in a research report on Friday. Benchmark restated a “buy” rating on shares of Incyte in a report on Tuesday, October 13th. Wells Fargo & Company reduced their price objective on Incyte from $128.00 to $127.00 and set an “equal weight” rating on the stock in a research note on Friday. Morgan Stanley assumed coverage on Incyte in a report on Tuesday, October 20th. They set an “equal weight” rating and a $119.00 target price for the company. Finally, Oppenheimer set a $152.00 target price on shares of Incyte in a research report on Tuesday. Twelve investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $132.90.

Insider Buying and Selling at Incyte

In other news, insider Pablo Cagnoni sold 2,642 shares of the company’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $112.71, for a total value of $297,779.82. Following the completion of the sale, the insider owned 183,200 shares of the company’s stock, valued at $20,648,472. This represents a 1.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 16.20% of the stock is owned by insiders.

Key Headlines Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Incyte reported third-quarter revenue of $1.56 billion, up 14% year over year and above the $1.46 billion analyst estimate. Adjusted loss of $3.60 per share was narrower than expected, helping support the stock. INCY Q3 Loss Narrower Than Expected, Sales Beat, FY’26 View Raised
• Positive Sentiment: The company raised 2026 total net-sales guidance to $5.21 billion-$5.30 billion, from $5.13 billion-$5.26 billion previously. Opzelura guidance was also increased to $1.10 billion-$1.12 billion, reflecting continued demand. Incyte signals 2026 net sales outlook as Opzelura guidance rises
• Positive Sentiment: Product trends were favorable: Opzelura sales rose 36% to $255 million, while hematology and oncology portfolio sales increased 38% to $235 million. Jakafi and Jakafi XR sales grew 4% to $827 million. Incyte Reports $1.56 Billion Third-Quarter Revenue and Raises 2026 Sales Guidance
• Positive Sentiment: Barclays raised its price target from $139 to $143 and maintained an “overweight” rating, implying substantial upside and reinforcing the bullish reaction. Barclays Incyte analyst recommendation
• Neutral Sentiment: Wells Fargo lowered its target slightly to $127 and kept an “equal weight” rating, while RBC raised its target to $117 but retained a “sector perform” rating. The changes indicate limited conviction among some analysts. Wells Fargo Incyte analyst recommendation
• Negative Sentiment: Incyte posted a GAAP loss largely because of a $1.23 billion in-process research and development charge tied to the Vega Therapeutics acquisition. The unusual charge obscures underlying operating strength and may keep investors focused on acquisition execution. Incyte Posts Q3 Loss on Vega Acquisition Charge

Incyte Trading Up 3.1%

NASDAQ:INCY opened at $120.39 on Friday. The firm’s fifty day simple moving average is $120.49 and its 200 day simple moving average is $108.14. Incyte Corporation has a twelve month low of $89.25 and a twelve month high of $132.60. The firm has a market capitalization of $24.40 billion, a price-to-earnings ratio of 64.04, a PEG ratio of 4.83 and a beta of 0.74.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.93) by $0.33. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The firm had revenue of $1.56 billion during the quarter, compared to the consensus estimate of $1.46 billion. During the same period in the prior year, the firm earned $2.26 EPS. The firm’s quarterly revenue was up 14.0% compared to the same quarter last year. On average, analysts predict that Incyte Corporation will post 1.97 earnings per share for the current year.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.